Nuwellis, Inc.

Equities

CHFS

US67113Y6032

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
4.27 ^USD	-6.77%		+16.99%	-79.00%

17/07	Nuwellis Marks First Commercial Sale of Quelimune Therapy to Cincinnati Children's	CI
09/07	Nuwellis, Inc. Announces New Clinical Evidence Demonstrating the Efficacy of its Aquadex® System to be Presented at HFSA 2024 Conference	CI

Sunshine Heart, Inc. announced that it has received $0.9 million in funding

January 11, 2017

On January 11, 2017, Sunshine Heart Inc. (NasdaqCM:SSH) closed the transaction. The company received $900,000 pursuant to exemption provided under Regulation D from two investors. The company received $200,000 in its second and final tranche close.

Latest news about Nuwellis, Inc.

Nuwellis Marks First Commercial Sale of Quelimune Therapy to Cincinnati Children's	17/07	CI
Nuwellis, Inc. Announces New Clinical Evidence Demonstrating the Efficacy of its Aquadex® System to be Presented at HFSA 2024 Conference	09/07	CI
Nuwellis Extends Pilot Program With Dialysis Services Provider DaVita	06/06	MT
Top Midday Gainers	07/05	MT
Nuwellis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Transcript : Nuwellis, Inc., Q1 2024 Earnings Call, May 07, 2024	07/05
Earnings Flash (NUWE) NUWELLIS Reports Q1 Revenue $1.9M, vs. Street Est of $2M	07/05	MT
Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology	02/05	CI
Maxim Downgrades Nuwellis to Hold	29/04	MT
Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	09/04	CI
Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days	07/03	CI
Nuwellis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	06/03	CI
Transcript : Nuwellis, Inc., Q4 2023 Earnings Call, Mar 05, 2024	05/03
Earnings Flash (NUWE) NUWELLIS Reports Q4 Revenue $2.6M	05/03	MT
Certain Warrants of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	16/01	CI
Certain Stock Options of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	16/01	CI
Certain Common Stock of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	16/01	CI
Nuwellis Receives FDA Approval for Specialized Catheter	05/01	MT
Nuwellis, Inc. Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter	05/01	CI
Nuwellis, Inc. Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring Foriatric Patients	28/11	CI
Ladenburg Thalmann Downgrades Nuwellis to Neutral From Buy	08/11	MT
Nuwellis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11	CI
Transcript : Nuwellis, Inc., Q3 2023 Earnings Call, Nov 07, 2023	07/11
Earnings Flash (NUWE) NUWELLIS Reports Q3 Revenue $2.4M	07/11	MT
Nuwellis, Inc. Announces Board of Directors Transition	01/11	CI

Chart Nuwellis, Inc.

Duration

Period

More charts

Company Profile

Nuwellis, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.

Sector

Advanced Medical Equipment & Technology

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Nuwellis, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.27

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
NUWELLIS, INC.	-79.00%	2.2M
THERMO FISHER SCIENTIFIC	+4.57%	212B
DANAHER CORPORATION	+8.61%	186B
INTUITIVE SURGICAL, INC.	+26.34%	151B
BOSTON SCIENTIFIC CORPORATION	+33.90%	114B
SIEMENS HEALTHINEERS AG	+2.28%	65.57B
EDWARDS LIFESCIENCES CORPORATION	+14.50%	52.61B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-3.30%	46.8B
AGILENT TECHNOLOGIES, INC.	-3.98%	38.95B
GE HEALTHCARE TECHNOLOGIES INC.	+6.66%	37.64B

Other Advanced Medical Equipment & Technology